Sigyn Therapeutics Reports Preliminary Results of Hepatic Encephalopathy Toxin Study

The goal of the hepatic toxin study was to collect supporting data that would expand the potential use of Sigyn Therapy to include chronic liver disease and acute liver failure indications, including HE.